Sign in

OLMA on Nasdaq

Olema Pharmaceuticals, Inc.

Olema Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the discovery.1 It is headquartered in San Francisco, California.1 Its shares trade on Nasdaq under the symbol OLMA.1

Price unavailable

Last updated Oct 21, 2026.

Overview

Compare with another stock.

  • TickerOLMA on Nasdaq1
  • IndustryPharmaceutical Preparations1
  • HeadquartersSan Francisco, California1
  • Incorporated inDE2
  • Business address780 Brannan Street, San Francisco, Ca 941032
  • Filer categoryNon-accelerated filer, Smaller reporting company2
  • Legal formCorporation

See how the biggest companies compare on our leaderboards

Olema is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of next-generation targeted therapies for breast cancer and beyond. We are advancing our pipeline of novel therapies by leveraging our deep understanding of endocrine-driven cancers, nuclear receptors, and mechanisms of acquired resistance.4 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Financial statements

Operating income56789-$178.7M in 2025+4034% since 2019
-$200.0M-$150.0M-$100.0M-$50.0M02019: -$4.3M-$4.3M20192020: -$21.5M-$21.5M2020+398%2021: -$71.5M-$71.5M2021+232%2022: -$107.0M-$107.0M2022+50%2023: -$105.0M-$105.0M2023−2%2024: -$142.3M-$142.3M2024+36%2025: -$178.7M-$178.7M2025+26%
Net income56789-$162.5M in 2025+3664% since 2019
-$200.0M-$150.0M-$100.0M-$50.0M02019: -$4.3M-$4.3M20192020: -$22.1M-$22.1M2020+413%2021: -$71.1M-$71.1M2021+221%2022: -$104.8M-$104.8M2022+47%2023: -$96.7M-$96.7M2023−8%2024: -$129.5M-$129.5M2024+34%2025: -$162.5M-$162.5M2025+25%

Every line of the income statement as filed: the last 2 fiscal years, latest first.9

Period ending2025-12-312024-12-31
Research and development$157.7M$124.5M
General and administrative$21.0M$17.7M
Total operating expenses$178.7M$142.3M
Loss from operations-$178.7M-$142.3M
Interest income$16.2M$12.7M
Other income$23.0K$102.0K
Total other income$16.2M$12.8M
Net loss-$162.5M-$129.5M
Net loss per share, basic (in dollars per share)-$1.87-$2.20
Net loss per share, diluted (in dollars per share)-$1.87-$2.20
Weighted average shares used to compute net loss per share, basic (in shares)87.0M shares58.7M shares
Weighted average shares used to compute net loss per share, diluted (in shares)87.0M shares58.7M shares
One-time milestone payments to Aurigene$10.0M$5.0M

Compare Olema Pharmaceuticals, Inc. with another company

Corporate structure

Olema Pharmaceuticals, Inc. sits at the top of its group. 3 entities, 3 countries on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of Olema Pharmaceuticals, Inc.

  • Olema Pharmaceuticals, Inc. San Francisco, California
    • Olema Oncology Australia PTY LTD Subsidiary · Australia
    • Olema Oncology International Limited Subsidiary · Ireland

Built from subsidiaries listed in Exhibit 21 of annual reports filed with the SEC; major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What Olema Pharmaceuticals, Inc. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Property and equipment, net$274.0K9 Dec 31, 2025$746.0K9 Dec 31, 2024−63.3%
Operating-lease assets (leased space)$1.1M9 Dec 31, 2025$1.3M9 Dec 31, 2024−12.8%

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$48.3M9 Dec 31, 2025$139.5M9 Dec 31, 2024−65.4%
Marketable securities, current$457.1M9 Dec 31, 2025$294.6M9 Dec 31, 2024+55.2%
Debt securities available for sale$505.6M9 Dec 31, 2025$434.7M9 Dec 31, 2024+16.3%

Properties, in its own words

Our corporate headquarters are located in San Francisco, California, where we lease approximately 16,500 square feet of office and laboratory space pursuant to lease agreements that expire between December 2026 and January 2027. We also have leased approximately 4,000 square feet of office space in Cambridge, Massachusetts that will expire in March 2027. We believe that these existing facilities will be adequate for our near-term needs. If required, we believe that suitable additional or alternative space would be available in the future on commercially reasonable terms.

Item 2 of the 10-K filed Mar 16, 2026.4

Leadership

Who has led Olema Pharmaceuticals, Inc., and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Sean Bohen2020–now

President

  1. Sean Bohen2020–now

Chief financial officer

  1. Jason O'Byrne2026–now
2025
Board members and other officers (22)

Named in SEC Form D filings

People the company listed in its private-offering notices.

  • Executive OfficerDavid C. Myles, Ph.D. named Sep 14, 2023 to Dec 12, 202434
  • Executive Officer, DirectorSean Bohen, M.D., Ph.D. named Sep 14, 2023 to Dec 12, 202434
  • DirectorCyrus L. Harmon, Ph.D. named Sep 14, 2023 to Dec 12, 202434
  • DirectorGorjan L. Hrustanovic, Ph.D. named Sep 14, 2023 to Dec 12, 202434
  • DirectorGraham L. Walmsley, M.D., Ph.D. named Sep 14, 2023 to Dec 12, 202434

Subsidiaries and ownership

Subsidiaries (Exhibit 21)

  • Olema Oncology Australia PTY LTD Australia3
  • Olema Oncology International Limited Ireland3

The subsidiaries the company lists in Exhibit 21 of its annual report, as filed.

Timeline

  1. Oct 15, 20268-K Executive or director change35
  2. Aug 13, 20268-K Executive or director change; Regulation FD disclosure36
  3. Aug 10, 20268-K Results of operations37
  4. Jun 23, 20268-K Shareholder vote38
  5. May 26, 20268-K Regulation FD disclosure; Other events39
  6. May 21, 20268-K Regulation FD disclosure; Other events40
  7. May 12, 20268-K Results of operations41
  8. May 1, 20268-K Entered a material agreement; New debt or obligation42
  9. Apr 29, 20268-K Executive or director change; Regulation FD disclosure43
  10. Mar 16, 20268-K Results of operations44
  11. Jan 30, 20268-K Executive or director change45
  12. Jan 12, 20268-K Results of operations; Regulation FD disclosure46
  13. Nov 18, 2020New chief executive Sean Bohen becomes CEO12

Calendar

Coming up

  1. Nov 9, 2026Reports results for the quarter ending Sep/2026 A year earlier it reported ($0.49) a share, on Nov 10, 2025.47

When it reported results

  1. Aug 10, 2026Reported quarterly or annual results37
  2. May 12, 2026Reported quarterly or annual results41
  3. Mar 16, 2026Reported quarterly or annual results44
  4. Jan 12, 2026Reported quarterly or annual results46
  5. Nov 10, 2025Reported quarterly or annual results48
  6. Aug 11, 2025Reported quarterly or annual results49
  7. May 13, 2025Reported quarterly or annual results50
  8. Mar 18, 2025Reported quarterly or annual results51

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

453 filings to the SEC since October 2021: 5 annual reports, 15 quarterly reports, 60 major events, 178 insider forms, 51 large holders, 2 private raises, 142 other. The latest 20:

  1. Oct 15, 20268-K EDGAR
  2. Sep 2, 20264 EDGAR
  3. Aug 13, 20263 EDGAR
  4. Aug 13, 20268-K EDGAR
  5. Aug 10, 202610-Q EDGAR
  6. Aug 10, 20268-K EDGAR
  7. Aug 6, 2026SCHEDULE 13G/A EDGAR
  8. Jul 29, 2026SCHEDULE 13G/A EDGAR
  9. Jul 27, 20264 EDGAR
  10. Jul 24, 2026144 EDGAR
  11. Jul 23, 2026144 EDGAR
  12. Jun 23, 20264 EDGAR
  13. Jun 23, 20264 EDGAR
  14. Jun 23, 20264 EDGAR
  15. Jun 23, 20264 EDGAR
  16. Jun 23, 20264 EDGAR
  17. Jun 23, 20264 EDGAR
  18. Jun 23, 20264 EDGAR
  19. Jun 23, 20264 EDGAR
  20. Jun 23, 20264 EDGAR

The 453 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

95 open-market trades by officers, directors and large owners since October 2021: 12 buys and 83 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Jul 24, 2026Harmon CyrusDirectorSale12,500$11.71$146.4KForm 4
Jul 23, 2026Harmon CyrusDirectorSale12,500$11.58$144.8KForm 4
Mar 4, 2026Mitchell ShawnteCHIEF LEGAL OFFICERSale25,000$24.25$606.4KForm 4
Mar 3, 2026Mitchell ShawnteCHIEF LEGAL OFFICERSale15,000$23.01$345.1KForm 4
Jan 20, 2026Harmon CyrusDirectorSale10,000$26.88$268.8KForm 4
Jan 15, 2026Kovacs Shane William CharlesCH. OPERATING & FINANCIAL OFF.Sale100,000$28.73$2.9MForm 4
Jan 14, 2026Harmon CyrusDirectorSale3,489$29.12$101.6KForm 4
Jan 14, 2026Myles David C.CH. DISCOV. & NON-CLIN DEV OFFSale50,000$28.87$1.4MForm 4
Jan 13, 2026Myles David C.CH. DISCOV. & NON-CLIN DEV OFFSale50,000$27.60$1.4MForm 4
Jan 13, 2026Kovacs Shane William CharlesCH. OPERATING & FINANCIAL OFF.Sale3,822$28.01$107.1KForm 4
Jan 12, 2026Myles David C.CH. DISCOV. & NON-CLIN DEV OFFSale10,000$28.34$283.4KForm 4
Dec 23, 2025Zojwalla NaseemCHIEF MEDICAL OFFICERSale99,509$27.66$2.8MForm 4
Dec 22, 2025Zojwalla NaseemCHIEF MEDICAL OFFICERSale100,000$28.04$2.8MForm 4
Dec 22, 2025Harmon CyrusDirectorSale2,881$28.53$82.2KForm 4
Dec 19, 2025Zojwalla NaseemCHIEF MEDICAL OFFICERSale70,000$28.20$2.0MForm 4
Dec 19, 2025Myles David C.CH. DISCOV. & NON-CLIN DEV OFFSale51,000$30.46$1.6MForm 4
Dec 19, 2025CLARK IAN TDirectorSale264,800$29.73$7.9MForm 4
Sep 18, 2025Harmon CyrusDirectorSale13,086$8.33$109.0KForm 4
Sep 16, 2025Harmon CyrusDirectorSale11,914$8.05$95.9KForm 4
Jan 8, 2025Bain Capital Life Sciences Investors, LLC10% ownerBuy300,000$5.76$1.7MForm 4

All 95 trades can be filtered by person here when JavaScript is on.

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Executive pay

What the company paid its top executives, from the summary compensation table in its proxy statement. Total pay includes salary, bonus, stock and option awards and other pay, as the company valued them.

YearExecutiveAgeSalaryTotal pay
2025Sean BohenM.D., Ph.D.$699.9K$3.2M68
2025Shawnte MitchellJ.D.48$391.9K$2.1M68
2025Shane Kovacs$562.6K$1.9M68
2024President and Chief Executive Officer$673.0K$8.1M68
2024Chief Operating and Financial Officer$541.0K$4.3M68

Money raised

Private offerings the company reported to the SEC on Form D.

  1. Dec 4, 2024Raised $250 million in a private offering of equity Form D: $250 million offered in all Form D
  2. Sep 5, 2023Raised $130 million in a private offering of equity Form D: 12 investors so far Form D

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 100. Change is in shares since the quarter before.

FundSharesValueShare of the fundChange
Fmr LLC12,143,062$151.9M0.0%+1,756,217
Paradigm Biocapital Advisors LP8,670,576$108.5M2.0%+650,000
Jupiter Topco LLC7,094,413$88.8M0.0%New
Bain Capital Life Sciences Investors, LLC7,085,249$88.6M5.3%−387,989
BlackRock, Inc.6,714,691$84.0M0.0%+1,062,556
Bvf Inc/il5,295,893$66.3M1.7%No change
Siren, L.L.C.4,856,949$60.8M1.2%+100,000
State Street Corp4,316,058$54.0M0.0%+378,227
Vanguard Capital Management LLC3,341,217$41.8M0.0%+257,700
Logos Global Management LP3,208,875$40.1M1.7%No change
Franklin Resources Inc2,349,586$29.4M0.0%+1,130,629
Cormorant Asset Management, LP2,150,000$26.9M1.4%−1,750,000
Morgan Stanley1,832,269$22.9M0.0%+616,579
Geode Capital Management, LLC1,819,029$22.8M0.0%+274,612
Vanguard Portfolio Management LLC1,663,218$20.8M0.0%+1,070,187
Goldman Sachs Group Inc1,567,979$19.6M0.0%+522,390
Deep Track Capital, LP1,500,000$18.8M0.3%New
Dimensional Fund Advisors LP1,416,533$17.7M0.0%+334,099
Lightspeed Management Company, L.l.c.1,355,299$17.0M0.7%No change
Kingdon Capital Management, L.l.c.1,200,000$15.0M2.0%+345,000
Two Sigma Investments, LP1,131,434$14.2M0.0%−37,987
Point72 Asset Management, L.P.1,070,949$13.4M0.0%+999,842
Defilade Capital Management, L.P.924,758$11.6M1.5%−579,778
Ameriprise Financial Inc840,646$10.5M0.0%+783,284
Woodline Partners LP751,030$9.4M0.0%−731,000

13F reports cover disclosed long positions in U.S. stocks only.

SEC filer profile

How Olema Pharmaceuticals, Inc. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGAROlema Pharmaceuticals, Inc.1
  • CIK0001750284
  • Employer ID (EIN)30-04097404
  • Filer statusNon-accelerated filer not an emerging growth company; a smaller reporting company; not a shell company4
  • Incorporated inDelaware4
  • Fiscal year endsDecember 311
  • Industry code (SIC)2834 Pharmaceutical Preparations1
  • SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance1
  • Business address780 Brannan Street, San Francisco, CA 941031
  • Phone(415) 651-33161
  • Shares outstanding87,497,607 as of Aug 6, 202611
  • Public float$243.1M as of Jun 30, 20254
  • AuditorErnst & Young LLP, New Jersey PCAOB ID 42; no auditor attestation of internal control over financial reporting4
  • On EDGAR sinceAug 27, 20181
  • Filings561 in all: 4 (203), 144 (97), 8-K (65), 3 (26), SC 13G/A (20), 10-Q (17), 4/A (14), SC 13G (14)1
    All 41 form types

    SCHEDULE 13G/A (13), CORRESP (7), S-8 (7), 10-K (6), DEF 14A (6), DEFA14A (6), UPLOAD (6), 424B5 (5), D (5), EFFECT (5), SC 13D/A (5), ARS (4), S-3 (4), SCHEDULE 13G (3), 424B3 (2), DRSLTR (2), SC 13D (2), SEC STAFF LETTER (2), 3/A (1), 424B4 (1), 8-A12B (1), 8-K/A (1), CERT (1), D/A (1), DEL AM (1), DRS (1), DRS/A (1), S-1 (1), S-1/A (1), S-1MEF (1), S-3ASR (1), S-3MEF (1), SCHEDULE 13D/A (1)

  • Latest filingsAnnual report (10-K) Mar 16, 2026
    Quarterly report (10-Q) Aug 10, 2026
    Proxy statement (DEF 14A) Apr 29, 2026
    Latest 8-K (8-K) Oct 15, 2026

Securities registered for trading

ClassSymbolExchange
Common StockOLMAThe Nasdaq Global Select Market

From the cover page of the 10-K filed Mar 16, 2026 (Section 12(b) of the Exchange Act).4

Risk factors and legal proceedings

The risks Olema Pharmaceuticals, Inc. names in Item 1A of its 10-K filed Mar 16, 2026: 75 risks under these headings, as written.4

  • Risks related to our financial position and the need for additional capital
  • We have no products approved for commercial sale, which may make it difficult for you to evaluate our current business and predict our future success and viability.
  • We require substantial additional capital to finance our operations. If we are unable to raise such capital when needed, or on acceptable terms, we may be forced to delay, reduce, and/or eliminate one or more of our research and drug development programs of our product candidates or future commercialization efforts.
  • We have incurred net losses since inception, and we expect to continue to incur net losses for the foreseeable future. In addition, we may be unable to continue as a going concern over the long term.
  • We have never generated revenue from product sales and may never be profitable.
  • The terms of the Loan Agreement place restrictions on our operating and financial flexibility. If we raise additional capital through debt financing, the terms of any new debt could further restrict our ability to operate our business.
  • Risks related to the discovery, development and commercialization of our product candidates
  • We are substantially dependent on the success of our lead product candidate, palazestrant, which is currently in clinical development. If we are unable to complete development of, obtain regulatory approval for, and commercialize palazestrant in one or more indications and in a timely manner, our business, financial condition, results of operations, and prospects will be significantly harmed.
  • The regulatory approval processes of the FDA, European Commission, and comparable foreign authorities are lengthy, time consuming and inherently unpredictable, and if we are ultimately unable to obtain regulatory approval for palazestrant, OP-3136, or any future product candidates we may develop, our business, financial condition, results of operations, and prospects will be significantly harmed.
  • Delays in clinical trials are common and have many causes, and any delay could result in increased costs to us and jeopardize or delay our ability to obtain regulatory approval and commence product sales.
  • Although we have received Fast Track designation for palazestrant for ER+/HER2- metastatic breast cancer that has progressed following one or more lines of endocrine therapy with at least one line given in combination with a CDK4/6 inhibitor, we may be unable to obtain or maintain the benefits associated with such designation.
  • Because we are pursuing a variety of target indications for palazestrant and OP-3136, we may expend our limited resources to pursue a particular indication and fail to capitalize on indications or additional product candidates that may be more profitable or for which there is a greater likelihood of success.
The other 64 risks
  • Even if approved, palazestrant or OP-3136 may not achieve adequate market acceptance among physicians, patients, healthcare payors, and others in the medical community necessary for commercial success.
  • If we experience delays or difficulties in the enrollment and/or maintenance of patients in clinical trials, our clinical development activities could be delayed or otherwise adversely affected.
  • We are developing palazestrant and OP-3136 and may develop future product candidates, in combination with other therapies, which exposes us to additional risks.
  • Risks associated with the in-licensing or acquisition of drug candidates could cause substantial delays in the pre-clinical and clinical development of our drug candidates.
  • The incidence and prevalence for target patient populations of palazestrant and OP-3136 are based on estimates and third-party sources. If the market opportunities for palazestrant, OP-3136, or any future product candidates we may develop, if and when approved, are smaller than we estimate or if any approval that we obtain is based on a narrower definition of the patient population, our revenue and ability to achieve profitability might be materially and adversely affected.
  • Interim, initial, “top-line” and preliminary data from our clinical trials that we announce or publish from time to time may change as more patient data become available and are subject to audit and verification procedures that could result in material changes in the final data.
  • We face significant competition, and if our competitors develop and market technologies or products more rapidly than we do or that are more effective, safer, or less expensive than palazestrant, OP-3136, or any future product candidates we may develop, our commercial opportunities will be negatively impacted.
  • Changes in methods of palazestrant and OP-3136 manufacturing or formulation may result in additional costs or delay.
  • Any product candidate we develop may become subject to unfavorable third-party coverage and reimbursement practices, as well as pricing regulations.
  • Guidelines and recommendations published by various organizations can reduce the use of palazestrant, OP-3136, or any future product candidates we may develop.
  • Risks related to regulatory approval and other legal compliance matters
  • We may be unable to obtain U.S. or foreign regulatory approvals and, as a result, may be unable to commercialize palazestrant, OP-3136, or any future product candidates we may develop.
  • Our business entails a significant risk of product liability and if we are unable to obtain sufficient insurance coverage, such inability could significantly harm our business, financial condition, results of operations, and prospects.
  • Palazestrant, OP-3136, and any future product candidates we develop may cause significant adverse events, toxicities or other undesirable side effects when used alone or in combination with other approved products or investigational new drugs, which may result in a safety profile that could inhibit regulatory approval, prevent market acceptance, limit their commercial potential or result in significant negative consequences.
  • The FDA, EMA, the European Commission, and other comparable foreign regulatory authorities may not accept data from trials conducted in locations outside of their jurisdiction.
  • Obtaining and maintaining regulatory approval of palazestrant, OP-3136, or any product candidate we develop in the future, in one jurisdiction does not mean that we will be successful in obtaining regulatory approval of palazestrant, OP-3136, or any product candidate we develop in the future, in other jurisdictions.
  • Even if palazestrant, OP-3136, or any product candidate we develop in the future, receives regulatory approval, it will be subject to significant post-marketing regulatory requirements and oversight.
  • The FDA and other regulatory authorities actively enforce the laws and regulations prohibiting the promotion of off-label uses.
  • We may face difficulties from changes to current regulations, policies, and future legislation.
  • We and the third parties with whom we work are subject to stringent and evolving U.S. and foreign laws, regulations, rules, contractual obligations, policies and other obligations related to data privacy and security. Our (or third parties with whom we work) actual or perceived failure to comply with such obligations could lead to regulatory investigations or actions; litigation; fines and penalties; disruptions of our business operations; reputational harm; loss of revenue or profits; and other adverse business consequences.
  • Our employees, independent contractors, consultants, commercial collaborators, principal investigators, CROs, suppliers and vendors may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements.
  • If we fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur costs that could significantly harm our business, financial condition, results of operations, or prospects.
  • Our research and development activities could be affected or delayed as a result of possible restrictions on animal testing.
  • Our business activities may be subject to the U.S. Foreign Corrupt Practices Act (FCPA) and similar anti-bribery and anti-corruption laws of other countries in which we operate, as well as U.S. and certain foreign export controls, trade sanctions, and import laws and regulations. Compliance with these legal requirements could limit our ability to compete in foreign markets and subject us to liability if we violate them.
  • Risks related to employee matters, managing our growth and other risks related to our business
  • Unfavorable U.S. and global macroeconomic and geopolitical conditions could adversely affect our business, financial condition, results of operations, and prospects.
  • International trade policies, including tariffs, sanctions and trade barriers may adversely affect our business, financial condition, results of operations, and prospects.
  • Our success is highly dependent on our ability to attract and retain highly skilled executive officers and employees.
  • We have never commercialized a product candidate before. If we are unable to establish sales, marketing, or distribution capabilities or enter into agreements with third parties to sell, market or distribute palazestrant, OP-3136, or any future product candidates we may develop, we may not be able to successfully sell, market or distribute palazestrant, OP-3136, or any future product candidate we may develop that obtain regulatory approval, if any.
  • In order to successfully implement our plans and strategies, we will need to grow the size of our organization, and we may experience difficulties in managing this growth.
  • If our information technology systems, our data or those of the third parties with whom we work are or were compromised, we could experience adverse consequences resulting from such compromise, including but not limited to regulatory investigations or actions; litigation; fines and penalties; disruptions of our business operations; reputational harm; loss of revenue or profits; or other adverse consequences.
  • EU drug marketing and reimbursement regulations may materially affect our ability to market and receive coverage for our products in the EU Member States.
  • Business disruptions could seriously harm our future revenue and financial condition and increase our costs and expenses.
  • Our ability to utilize our net operating loss carryforwards and certain other tax attributes may be limited.
  • A variety of risks associated with international marketing of palazestrant, OP-3136, or any future product candidates we may develop, if approved, could significantly harm our business, financial condition, results of operations, and prospects.
  • Risks related to our intellectual property
  • Our success depends on our ability to protect our intellectual property and our proprietary technologies.
  • If the scope of any patent protection we obtain is not sufficiently broad, or if we lose any of our patent protection, our ability to prevent our competitors from commercializing similar or identical product candidates would be adversely affected.
  • Intellectual property rights do not necessarily address all potential threats to our competitive advantage.
  • Our commercial success depends significantly on our ability to operate without infringing, misappropriating or otherwise violating the patents and other proprietary rights of third parties. Claims by third parties that we infringe, misappropriate or otherwise violate their proprietary rights may result in liability for damages or prevent or delay our developmental and commercialization efforts.
  • We may not be successful in obtaining or maintaining necessary rights from third parties for what we identify as necessary for palazestrant or OP-3136 through acquisitions and in-licenses.
  • We may be involved in lawsuits to protect or enforce our patents, which could be expensive, time- consuming and unsuccessful. Further, our issued patents could be found invalid or unenforceable if challenged in court.
  • Intellectual property litigation may lead to unfavorable publicity that harms our reputation and causes the market price of our common shares to decline.
  • Derivation proceedings may be necessary to determine priority of inventions, and an unfavorable outcome may require us to cease using the related technology or to attempt to license rights from the prevailing party.
  • Changes in patent laws or their interpretations could increase the uncertainties and costs surrounding the prosecution of our patent applications or those of our licensors and the enforcement or defense of our issued patents or those of our licensors.
  • Changes in U.S. patent law, or laws in other countries, could diminish the value of patents in general, thereby impairing our ability to protect palazestrant, OP-3136, or any future product candidates we may develop.
  • We may be subject to claims challenging the inventorship or ownership of our patents and other intellectual property.
  • Patent terms may be inadequate to protect our competitive position on palazestrant, OP-3136, or any future product candidates we may develop for an adequate amount of time.
  • If we do not obtain patent term extension for palazestrant, OP-3136, or any future product candidates we may develop, our business, financial condition, results of operations, and prospects may be significantly harmed.
  • We will not be able to protect our intellectual property rights throughout the world.
  • Obtaining and maintaining our patent protection depends on compliance with various procedural, documentary, fee payment, and other requirements imposed by regulations and governmental patent authorities, and our patent protection could be reduced or eliminated for non-compliance with these requirements.
  • If our trademarks and trade names are not adequately protected, then we may not be able to build name recognition in our markets of interest and our business, financial condition, results of operations, and prospects could be significantly harmed.
  • If we are unable to protect the confidentiality of our trade secrets, our business, financial condition, results of operations, prospects, and competitive position would be significantly harmed.
  • We may be subject to claims that we or our employees have wrongfully used or disclosed alleged confidential information or trade secrets.
  • Our rights to develop and commercialize our technology and product candidates may be subject, in part, to the terms and conditions of licenses granted to us by others.
  • If we fail to comply with our obligations in the agreements under which we license intellectual property rights from third parties or otherwise experience disruptions to our business relationships with our licensors, we could lose license rights that are important to our business.
  • Intellectual property discovered through government funded programs may be subject to federal regulations such as “march-in” rights, certain reporting requirements and a preference for U.S.-based companies. Compliance with such regulations may limit our exclusive rights and limit our ability to contract with non-U.S. manufacturers.
  • Risks related to our dependence on third parties
  • We rely, and expect to continue to rely, on third parties, including independent clinical investigators and CROs, to conduct certain aspects of our non-clinical studies and clinical trials. If these third parties do not successfully carry out their contractual duties, comply with applicable regulatory requirements or meet expected deadlines, we may not be able to obtain regulatory approval for or commercialize palazestrant, OP-3136, or future product candidates we may develop and our business, financial condition, results of operations, and prospects could be significantly harmed.
  • The manufacture of drugs is complex, and our third-party manufacturers may encounter difficulties in production. If any of our third-party manufacturers encounter such difficulties, our ability to provide adequate supply of palazestrant or OP-3136 for clinical trials or our products for patients, if approved, could be delayed or prevented.
  • We have engaged in and may in the future engage in additional acquisitions, strategic partnerships or in-licensing opportunities, that may increase our capital requirements, dilute our stockholders, cause us to incur debt or assume contingent liabilities, and subject us to other risks.
  • We have entered into collaborations with third parties for the development and commercialization of palazestrant. If those collaborations are not successful, we may not be able to capitalize on the market potential of palazestrant.
  • If we decide to establish collaborations in the future but are not able to establish those collaborations on commercially reasonable terms or at all, we may have to alter our development and commercialization plans.
  • Risks Related to Ownership of Our Common Stock
  • An active trading market for our common stock may not be sustained.
  • The price of our stock has been and may continue to be volatile, and you could lose all or part of your investment.
  • Our quarterly operating results may fluctuate significantly or may fall below the expectations of investors or securities analysts, each of which may cause our stock price to fluctuate or decline.
  • Our principal stockholders and management own a significant percentage of our stock and will be able to exert significant control over matters subject to stockholder approval.

Legal proceedings

From time to time, we may become involved in legal proceedings or be subject to claims arising in the ordinary course of our business. We are not currently a party to any material legal proceedings. Regardless of outcome, such proceedings or claims can have an adverse impact on us because of defense and settlement costs, diversion of resources and other factors, and there can be no assurances that favorable outcomes will be obtained.

The opening of Item 3, Legal Proceedings.4

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44
  45. 45
  46. 46
  47. 47
  48. 48
  49. 49
  50. 50
  51. 51
  52. 52
  53. 53
  54. 54
  55. 55
  56. 56
  57. 57
  58. 58
  59. 59
  60. 60
  61. 61
  62. 62
  63. 63
  64. 64
  65. 65
  66. 66
  67. 67
  68. 68